OncoMatch/Clinical Trials/NCT06954246
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Is NCT06954246 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including MHB088C for and Topotecan for small cell lung cancer extensive stage.
Treatment: MHB088C for · Topotecan · Irinotecan · Paclitaxel — This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: CD276 any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage IV
Extensive-stage SCLC with disease progression after at least two cycles of platinum-based and PD-1/L1 systemic therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
disease progression after at least two cycles of platinum-based and PD-1/L1 systemic therapy
Must have received: anti-PD-1 therapy
disease progression after at least two cycles of platinum-based and PD-1/L1 systemic therapy
Must have received: anti-PD-L1 therapy
disease progression after at least two cycles of platinum-based and PD-1/L1 systemic therapy
Cannot have received: topoisomerase I inhibitor (topotecan, irinotecan)
Previous or ongoing treatment with topoisomerase I inhibitors, including antibody-drug conjugates (ADCs) containing topoisomerase I inhibitor payloads.
Cannot have received: B7-H3-targeted therapy
Prior B7-H3-targeted therapy.
Cannot have received: chemotherapy
Exception: within 4 weeks prior to the first administration of study drug
Receipt of chemotherapy within 4 weeks prior to the first administration of study drug
Cannot have received: radiotherapy
Exception: within 4 weeks prior to the first dose
receipt of radiotherapy ... within 4 weeks prior to the first dose
Cannot have received: biologics
Exception: within 4 weeks prior to the first dose
receipt of biologics ... within 4 weeks prior to the first dose
Cannot have received: endocrine therapy
Exception: within 4 weeks prior to the first dose
receipt of endocrine therapy ... within 4 weeks prior to the first dose
Cannot have received: immunotherapy
Exception: within 4 weeks prior to the first dose
receipt of immunotherapy ... within 4 weeks prior to the first dose
Cannot have received: other anti-tumor therapy
Exception: within 4 weeks prior to the first dose
receipt of other anti-tumor therapy ... within 4 weeks prior to the first dose
Lab requirements
Blood counts
Sufficient bone marrow and organ function
Kidney function
Sufficient bone marrow and organ function
Liver function
Sufficient bone marrow and organ function
Sufficient bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify